Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Esophageal Neoplasms × eprenetapopt × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Myeloproliferative Disorders 2 Leukemia, Myelomonocytic, Chronic 2 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Leukemia, Myeloid, Acute 1 Esophageal Neoplasms 1

Interventions

Cisplatin 109 Radiotherapy 100 Fluorouracil 89 Paclitaxel 75 Oxaliplatin 62 Docetaxel 56 Carboplatin 54 Irinotecan 41 Esophagectomy 41 Leucovorin 39 Capecitabine 39 Radiation 36 Surgical Procedures, Operative 35 Drug Therapy 31 Neoadjuvant Therapy 25 Chemoradiotherapy 18 Cetuximab 18 S 1 (combination) 17 pembrolizumab 16 camrelizumab 16 Nivolumab 15 Magnetic Resonance Spectroscopy 15 Bevacizumab 15 Blood Specimen Collection 14 Surveys and Questionnaires 12 Radiotherapy, Intensity-Modulated 12 Epirubicin 11 Biopsy 11 Trastuzumab 10 Immunotherapy 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02999893 2021-12-13

APROC

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡